Of Genentech's many accomplishments in 1999, it's patients like Nathan Zolezzi who remain the true measure of our success. Afflicted with allergic asthma, Nathan participated in a clinical trial of anti-IgE, a monoclonal antibody for the treatment of allergic disease. Positive Phase III results were announced in early 2000.